Bladder, kidney, and other urologic cancers:

Indications for: PADCEV

Locally advanced or metastatic urothelial cancer (mUC) in adults who have previously received a programmed death receptor-1 (PD-1) or programmed death-ligand 1 (PD-L1) inhibitor and platinum-containing chemotherapy, or are ineligible for cisplatin-containing chemotherapy and have previously received ≥1 prior lines of therapy.

Adult Dosage:

Give by IV infusion over 30mins. 1.25mg/kg (max 125mg) on Days 1, 8 and 15 of a 28-day cycle; continue until disease progression or unacceptable toxicity. Dose modifications: see full labeling.

Children Dosage:

Not established.

Boxed Warning:

Serious skin reactions.

PADCEV Warnings/Precautions:

Severe cutaneous reactions (including SJS, TEN); monitor closely. Consider withholding for persistent or recurrent Grade 2 skin reactions until Grade ≤1. Withhold, consult a specialist to confirm for suspected SJS, TEN or for Grade 3 reactions; permanently discontinue if confirmed SJS or TEN, Grade 4 or recurrent Grade 3 reactions occur. Monitor blood glucose levels in patients with, or at risk of, diabetes or hyperglycemia; withhold dose if blood glucose >250mg/dL. Monitor for pneumonitis; withhold if persistent or recurrent Grade 2 pneumonitis occurs until Grade ≤1; permanently discontinue if Grade 3 or 4 pneumonitis occurs. Monitor for new or worsening symptoms of peripheral neuropathy; consider dose interruption/reduction if occurs; permanently discontinue if Grade ≥3 reaction. Monitor for ocular disorders; if symptoms occur, consider ophthalmologic exam; interrupt/reduce dose if needed. Moderate or severe hepatic impairment (total bilirubin >1.5×ULN and any AST): avoid. Embryo-fetal toxicity. Advise to use effective contraception during and for 2 months (females) and for 4 months (males w. female partners) after the last dose. Pregnancy: exclude status prior to initiation. Nursing mothers: not recommended (during and for ≥3 weeks after the last dose).

PADCEV Classification:

Nectin-4 directed antibody-drug conjugate.

PADCEV Interactions:

May be potentiated by dual P-gp and strong CYP3A4 inhibitors (eg, ketoconazole); monitor closely. May be antagonized by dual P-gp and strong CYP3A4 inducers (eg, rifampin).

Adverse Reactions:

Fatigue, peripheral neuropathy, decreased appetite, rash, alopecia, nausea, dysgeusia, diarrhea, dry eye, pruritus, decreased weight, dry skin, lab abnormalities (increased AST/ALT, increased glucose, increased creatinine, decreased lymphocytes, decreased hemoglobin, decreased neutrophils, decreased platelets, decreased phosphate, decreased albumin, decreased sodium, increased urate, increased lipase); infusion-site extravasation (discontinue if occurs).

Generic Drug Availability:


How Supplied:

Single-dose vial—1